Lundbeck kick-starts new R&D strategy with Genmab and Merck deals
This article was originally published in Scrip
Executive Summary
Lundbeck has wasted little time implementing its new R&D strategy, signing a CNS antibody research deal with Genmab and acquiring rights to Merck & Co's antipsychotic Sycrest (asenapine) outside the US, China and Japan.